ERBB2 and breast carcinoma: Even though the retrospective monocentric design with the associated potential biases is a limitation of our study, it is—to our knowledge—the first study comparing molecular and transcriptomic profiles of H2L breast carcinomas with those of HER2-negative and HER2-positive carcinomas, and analyzing the main intracellular signaling pathways linked to HER2 expression.